Atria Investments Inc Purchases New Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Atria Investments Inc acquired a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 3,005 shares of the medical equipment provider’s stock, valued at approximately $330,000.

Several other institutional investors also recently modified their holdings of LNTH. Moloney Securities Asset Management LLC bought a new position in shares of Lantheus during the 3rd quarter worth about $1,066,000. Hancock Whitney Corp boosted its holdings in Lantheus by 265.6% during the first quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock valued at $1,254,000 after purchasing an additional 14,639 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Lantheus in the 2nd quarter valued at approximately $290,000. Van ECK Associates Corp raised its holdings in shares of Lantheus by 58.6% in the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock worth $6,469,000 after buying an additional 21,604 shares in the last quarter. Finally, Swedbank AB raised its holdings in shares of Lantheus by 21.1% in the 3rd quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock worth $79,266,000 after buying an additional 125,843 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Up 3.7 %

Shares of NASDAQ:LNTH opened at $90.52 on Friday. The firm has a market cap of $6.29 billion, a P/E ratio of 14.97 and a beta of 0.51. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89. The company’s 50-day moving average price is $103.43 and its two-hundred day moving average price is $96.53.

Wall Street Analysts Forecast Growth

LNTH has been the topic of several recent analyst reports. JMP Securities decreased their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. Redburn Atlantic started coverage on shares of Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price on the stock. Truist Financial reiterated a “buy” rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Finally, StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $122.50.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.